Sanofi and Maze Deal for MZE001 Terminated
Sanofi's agreement with Maze Therapeutics for the development of MZE001 was terminated following an FTC complaint. Explore the implications of this decision.
Topic
Sanofi
A collection of 3 issues
Sanofi Ends Maze Licensing Deal Over FTC Concerns
Sanofi has terminated its global licensing agreement with Maze Therapeutics for Pompe disease treatment, citing issues related to FTC regulations.
Sanofi to Increase Prices on Vaccines
Sanofi plans to hike prices on its vaccine portfolio, impacting healthcare costs. Discover more about the upcoming changes in pharmaceutical pricing.